$6.14 0.47 (+8.33%)
2/10/2012 4:00 PM

Exelixis, Inc. (NASDAQ:EXEL)

CAPS Rating: 4 out of 5

A development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases.

Recs

0
Player Avatar apiperisdown (84.23) Submitted: 11/5/2008 6:37:58 PM : Outperform Start Price: $3.38 EXEL Score: +35.77

Insider buying indicates that they are not that bummed that GSK passed. CEO put a million dollar bet on his company right before Halloween. Trick? or Treat? I'm gonna take a shot and say treat. Giddy up.

Report this Post Add Comment

Featured Broker Partners


Advertisement